MARKET

UNCY

UNCY

Unicycive Therapeutics Inc
NASDAQ
5.38
+0.38
+7.60%
Opening 13:39 08/12 EDT
OPEN
5.14
PREV CLOSE
5.00
HIGH
5.49
LOW
5.04
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
8.74
52 WEEK LOW
3.710
MARKET CAP
147.37M
P/E (TTM)
-2.5897
1D
5D
1M
3M
1Y
5Y
1D
Unicycive Therapeutics GAAP EPS of -$0.06 beats by $0.27
Seeking Alpha · 6h ago
*Unicycive Therapeutics: Unaudited Cash, Cash Equivalents, and Marketable Securities Totaled $61.4M at June 30, With Expected Runway Into 2027 >UNCY
Dow Jones · 6h ago
Press Release: Unicycive Therapeutics Announces -2-
Dow Jones · 6h ago
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) Estimate
Benzinga · 6h ago
Weekly Report: what happened at UNCY last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at UNCY last week (0727-0731)?
Weekly Report · 08/03 09:34
Weekly Report: what happened at UNCY last week (0720-0724)?
Weekly Report · 07/27 09:36
Unicycive Therapeutics: Two CRLs, One Fixable Problem
Seeking Alpha · 07/25 14:01
More
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Webull offers Unicycive Therapeutics Inc stock information, including NASDAQ: UNCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UNCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UNCY stock methods without spending real money on the virtual paper trading platform.